U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
912 articles with Allergan, Inc.
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
Allergan has gone to great lengths to defend the patents for its blockbuster dry-eye drug Restasis and it looks like the company will have to head back to court again.
5/18/2018Amgen and Novartis scored a big win in the migraine market late Thursday when the U.S. Food and Drug Administration approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults.
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Evolus for its Biologics License Application (BLA) for DWP-450 (prabotulinumtoxinA), a drug to treat frown lines similar to Allergan’s Botox.
The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
Approximately 25 percent of adults in the United States will deal with some form of mental illness within a given year. It’s also estimated that many of the people who experience these problems may never report it or seek help.
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Commercial Officer William Meury will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas, Nevada.
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Allergan to Present Data from a Robust Mental Health Clinical Program at the American Psychiatric Association (APA) 2018 Annual Meeting
Eight accepted abstracts will showcase new data across schizophrenia, bipolar I disorder and major depressive disorder (MDD)
Allergan plc announced that Chief Financial Officer Matthew Walsh will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston, Massachusetts.
Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action
Allergan plc and Ironwood Pharmaceuticals, Inc. announced the launch of the AboutYourGut.com website.
Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting
Allergan Chief Executive Officer Brent Saunders delivered a rosy review of the first quarter for 2018, including a 3 percent growth in revenue to $3.67 billion over the past three months. However, investors are not terribly pleased and shares have fallen nearly 4 percent this morning.
Allergan plc reported its first quarter 2018 continuing operations performance. Total first quarter 2018 net revenues were $3.67 billion, a 2.8 percent increase from the prior year quarter.
Shares of Allergan have been in decline for more than a year and that has created an opening for some investors to begin rattling sabers about change at the company.
Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Allergan plc announced positive results from ACHIEVE II (UBR-MD-02), the second of two pivotal Phase 3 clinical trials evaluating the efficacy, safety and tolerability of orally administered ubrogepant 25 mg and ubrogepant 50 mg compared to placebo in a single migraine attack in adults. Allergan anticipates filing of a New Drug Application (NDA) to the FDA in 2019.
Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018
Allergan plc, will present new data at the annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) in Austin, Texas from April 27-30, 2018.